You searched for "intravitreal"
Intravitreal injection related endophthalmitis
This article reviews the incidence, clinical findings, risk factors, management and visual outcomes in intravitreal injection related endophthalmitis. Incidence of this complication is reported to be in the range of 0.038% to 0.065% (1 in 2000-3000 injections). Patients present typically...
2018 update on intravitreal injections
In this review article the authors have highlighted the standardised and structured approach to intravitreal injections (IVI) by examining the recent evidence-based literature. IVI is the most commonly performed procedure worldwide with low potential risk of endophthalmitis. IOP spikes are...
Intravitreal afibercept and ranibizumab for PCV
This is a retrospective, interventional series comprising 98 eyes with polypidal choroidal vasculopathy (PCV) with the aim of comparing treatments with afibercept and ranibizumab, highlighting any differences in their efficacy. Case notes and imaging (FFA / ICG / OCT) were...
Endophthalmitis after intravitreal injections in France
In this nationwide, retrospective, multicentre case series, the authors looked at the incidence and characteristics of endophthalmitis after intravitreal injections of anti-VEGFs and steroids, given for a variety of posterior segment conditions (macular oedema secondary to diabetes or retinal vein...
Antibiotic prophylaxis after intravitreal injections
The use of topical antibiotics as prophylaxis after intravitreal injections is a contentious issue, especially now with increasing use of intravitreal anti-VEGF agents. In the Wills Eye Institute, prior to May 2011, all patients undergoing intravitreal injections in the office...
An alternative to povidone-iodine for intravitreal injections?
While povidone-iodine (5% aqueous) preparations have historically been considered the most effective antimicrobial prophylaxis for ophthalmic procedures and have been adopted as routine for intravitreal injections, post-procedure pain is a commonly recognized adverse event of IVI and has typically been...
Intravitreal aflibercept for diabetic macular oedema
The VISTA and VIVID randomised phase 3 trial were designed to compare the efficacy and safety of intravitreal aflibercept injections versus laser photocoagulation for diabetic macular oedema (DMO). A total of 872 patients with centrally involving DMO were recruited, and...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Intravitreal triamcinolone for uveitic macular oedema
This paper from South Korea reports on a prospective, double blind, randomised clinical study designed to evaluate the additional benefit of intravitreal triamcinolone (TA) administration for noninfectious uveitic macular oedema as an adjunct therapy to systemic anti-inflammatory treatment. Patients were...
Intravitreal Ziv-Aflibercept: safety analysis
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...
Intravitreal ranibizumab for the treatment of myopic CNV
The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...
